Evidence Base for the Use of PRRT

Area of Science:

• Nuclear Medicine
• Oncology
• Pharmacology

Background:

• Peptide receptor radionuclide therapy (PRRT) development for neuroendocrine tumors (NETs) faced challenges in clinical translation and regulatory processes.
• Early studies lacked rigorous data, despite growing evidence of PRRT's efficacy in improving survival and symptom relief for approximately 80% of patients.

Purpose of the Study:

• To evaluate the efficacy and safety of PRRT compared to standard treatment in patients with neuroendocrine tumors.
• To establish PRRT as a definitive treatment option for hormone-refractory NETs.

Main Methods:

• A decade and a half of research culminated in a formal randomized controlled trial.
• The trial compared PRRT directly against high-dose somatostatin therapy.

Main Results:

• PRRT demonstrated a positive benefit in survival and symptom relief in a significant majority of patients.
• The randomized trial conclusively proved PRRT's safety and effectiveness.

Conclusions:

• PRRT is a safe and effective treatment for neuroendocrine tumors.
• PRRT is the treatment of choice for hormone-refractory NETs, offering improved outcomes.